TOKYO, Jan 10 (Reuters) – Japan’s Takeda Pharmaceutical Co
Ltd expects annual sales from new lung cancer drug
brigatinib, added to its portfolio with the acquisition of Ariad
Pharmaceuticals Inc,…
The post Japan’s Takeda expects annual sales of Ariad’s lung cancer drug to exceed $1 bln appeared first on NASDAQ.